Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures

IF 4.6 2区 医学 Q1 NEUROSCIENCES
Carina Joy Donegan , Dimitri Daldegan-Bueno , Tehseen Noorani , Rachael Sumner , Anna Forsyth , William Evans , Todd Smith , Nicholas Hoeh , Frederick Sundram , David Menkes , Suresh Muthukumaraswamy , Lisa Reynolds
{"title":"Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures","authors":"Carina Joy Donegan ,&nbsp;Dimitri Daldegan-Bueno ,&nbsp;Tehseen Noorani ,&nbsp;Rachael Sumner ,&nbsp;Anna Forsyth ,&nbsp;William Evans ,&nbsp;Todd Smith ,&nbsp;Nicholas Hoeh ,&nbsp;Frederick Sundram ,&nbsp;David Menkes ,&nbsp;Suresh Muthukumaraswamy ,&nbsp;Lisa Reynolds","doi":"10.1016/j.neuropharm.2025.110670","DOIUrl":null,"url":null,"abstract":"<div><div>Expectations can impact antidepressant treatment and psychedelic therapy, often enhancing placebo effects and influencing outcomes. However, research in this context is lacking. Our study explored the expectations of participants with major depressive disorder (MDD) before microdosing lysergic acid diethylamide (LSD) in an open-label trial. Twenty-three individuals with MDD completed a semi-structured interview about their expectations before commencing an LSD microdosing regimen. Interviews were transcribed and analysed using qualitative content analysis and compared with Credibility/Expectancy Questionnaire scores. Response categories were motivation, influence, expected effects, expected mechanisms, and hope. Over half of the participants (16/23 participants) cited previous treatment failure as a motivation for participating, with additional motivations including long-term depression (7/23), interest in psychedelics (9/23), desire for microdosing to be available to others (4/23) and recommendation by a professional (2/23). Media (12/23) and friends/family (5/23) were major influences on microdosing opinions, as was the desire to avoid influence (10/23). Participants expected various effects, including changes to consciousness (5/23), subtle effects (10/23) or had no expectations (12/23). Some participants were unsure about mechanisms (7/23), but others believed microdosing might cause neural rewiring (11/23) or changes to thought patterns (7/23). Participants were optimistic (8/23), cautious (11/23), and/or excited about the research (7/23). Our study highlights the role of media in shaping expectations and the extent to which participants expect healing through psychedelics. Hope acted as a motivator and a disappointment buffer. Future research should develop a psychedelic-specific expectancy measure covering additional factors not covered by current measures.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"280 ","pages":"Article 110670"},"PeriodicalIF":4.6000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028390825003788","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Expectations can impact antidepressant treatment and psychedelic therapy, often enhancing placebo effects and influencing outcomes. However, research in this context is lacking. Our study explored the expectations of participants with major depressive disorder (MDD) before microdosing lysergic acid diethylamide (LSD) in an open-label trial. Twenty-three individuals with MDD completed a semi-structured interview about their expectations before commencing an LSD microdosing regimen. Interviews were transcribed and analysed using qualitative content analysis and compared with Credibility/Expectancy Questionnaire scores. Response categories were motivation, influence, expected effects, expected mechanisms, and hope. Over half of the participants (16/23 participants) cited previous treatment failure as a motivation for participating, with additional motivations including long-term depression (7/23), interest in psychedelics (9/23), desire for microdosing to be available to others (4/23) and recommendation by a professional (2/23). Media (12/23) and friends/family (5/23) were major influences on microdosing opinions, as was the desire to avoid influence (10/23). Participants expected various effects, including changes to consciousness (5/23), subtle effects (10/23) or had no expectations (12/23). Some participants were unsure about mechanisms (7/23), but others believed microdosing might cause neural rewiring (11/23) or changes to thought patterns (7/23). Participants were optimistic (8/23), cautious (11/23), and/or excited about the research (7/23). Our study highlights the role of media in shaping expectations and the extent to which participants expect healing through psychedelics. Hope acted as a motivator and a disappointment buffer. Future research should develop a psychedelic-specific expectancy measure covering additional factors not covered by current measures.
即将开始LSD微剂量治疗的抑郁症参与者期望的定性内容分析:确定致幻剂期望测量的需要。
期望可以影响抗抑郁治疗和迷幻治疗,经常增强安慰剂效应并影响结果。然而,这方面的研究还很缺乏。我们的研究在一项开放标签试验中探讨了重度抑郁症(MDD)患者在微剂量麦角酸二乙胺(LSD)前的期望。23名重度抑郁症患者在开始服用微剂量LSD之前完成了一项关于他们期望的半结构化访谈。访谈记录下来,使用定性内容分析进行分析,并与可信度/期望问卷得分进行比较。反应类别为动机、影响、预期效果、预期机制和希望。超过一半的参与者(16/23)将之前的治疗失败作为参与的动机,其他动机包括长期抑郁(7/23),对迷幻药的兴趣(9/23),希望其他人可以获得微剂量(4/23)和专业人士的建议(2/23)。媒体(12/23)和朋友/家人(5/23)是影响微剂量意见的主要因素,避免影响的愿望也是如此(10/23)。参与者期望各种影响,包括意识的变化(5/23),微妙的影响(10/23)或没有期望(12/23)。一些参与者不确定机制(7/23),但其他人认为微剂量可能会导致神经重新布线(11/23)或思维模式的改变(7/23)。参与者对研究持乐观(8/23)、谨慎(11/23)和/或兴奋(7/23)态度。我们的研究强调了媒体在塑造期望中的作用,以及参与者期望通过迷幻剂治愈的程度。希望是一种激励和失望缓冲。未来的研究应该开发一种针对致幻剂的预期指标,涵盖当前指标未涵盖的其他因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuropharmacology
Neuropharmacology 医学-神经科学
CiteScore
10.00
自引率
4.30%
发文量
288
审稿时长
45 days
期刊介绍: Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信